Published in Stress on July 28, 2010
The epigenetic landscape of alcoholism. Int Rev Neurobiol (2014) 0.91
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
A role for brain stress systems in addiction. Neuron (2008) 4.71
Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry (2007) 4.37
Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry (2006) 3.55
Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res (2002) 3.11
Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology (1998) 2.96
Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend (1998) 2.94
Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci (1995) 2.70
Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science (1997) 2.50
Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology (Berl) (2003) 2.27
Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron (1998) 2.13
Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci (2001) 2.09
Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) (2001) 1.94
Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav (2002) 1.75
Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci (2003) 1.72
Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res Brain Res Rev (1997) 1.61
Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci (1996) 1.59
Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct (2008) 1.54
Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron (2006) 1.54
Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl) (1999) 1.46
Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res (1995) 1.43
Reactivity to laboratory stress provocation predicts relapse to cocaine. Drug Alcohol Depend (2009) 1.42
Aggression and defeat: persistent effects on cocaine self-administration and gene expression in peptidergic and aminergic mesocorticolimbic circuits. Neurosci Biobehav Rev (2004) 1.37
In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse (1999) 1.28
Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. Arch Gen Psychiatry (2009) 1.17
Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc Natl Acad Sci U S A (2004) 1.15
Endocrine and gene expression changes following forced swim stress exposure during cocaine abstinence in mice. Psychopharmacology (Berl) (2008) 1.14
Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"-pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther (1996) 1.14
Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Eur J Neurosci (2008) 1.12
Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropin-releasing factor (CRF)-mediated mechanism. Brain Res (1987) 1.08
Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience (2002) 1.07
Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone. Peptides (1988) 1.07
Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology (1998) 1.06
The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci U S A (2004) 1.00
Increased CRH mRNA levels in the rat amygdala during short-term withdrawal from chronic 'binge' cocaine. Brain Res Mol Brain Res (2003) 1.00
Tissue plasminogen activator is required for corticostriatal long-term potentiation. Eur J Neurosci (2002) 0.99
Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem (2000) 0.98
Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc Natl Acad Sci U S A (2007) 0.96
Diurnal variations in plasma ACTH, cortisol and beta-endorphin levels in cocaine addicts. Horm Res (1992) 0.93
Restraint-induced corticosterone secretion and hypothalamic CRH mRNA expression are augmented during acute withdrawal from chronic cocaine administration. Neurosci Lett (2007) 0.92
Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci U S A (2009) 0.92
Glucocorticoid negative feedback in methadone-maintained former heroin addicts with ongoing cocaine dependence: dose-response to dexamethasone suppression. Addict Biol (2006) 0.92
Neuroendocrine-related effects of long-term, 'binge' cocaine administration: diminished individual differences in stress-induced corticosterone response. Neuroendocrinology (1998) 0.90
Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. Neurosci Lett (1995) 0.90
Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biol Psychiatry (1995) 0.88
Regional binding to corticotropin releasing factor receptors in brain of rats exposed to chronic cocaine and cocaine withdrawal. Synapse (1997) 0.88
Neuroendocrine responses to cocaine do not exhibit sensitization following repeated cocaine exposure. Life Sci (1992) 0.88
Evidence for beta1-adrenergic receptor involvement in amygdalar corticotropin-releasing factor gene expression: implications for cocaine withdrawal. Neuropsychopharmacology (2008) 0.87
Chronic cocaine administration sensitizes behavioral but not neuroendocrine responses. Brain Res (1991) 0.87
Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization. Genes Brain Behav (2007) 0.86
Acute effects of cocaine on plasma adrenocorticotropic hormone, luteinizing hormone and prolactin levels in cocaine-dependent men. J Pharmacol Exp Ther (1992) 0.85
Cocaine-mediated supersensitivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon. Neuroscience (2006) 0.84
Effects of saline substitution on responding and plasma corticosterone in rats trained to self-administer different doses of cocaine. J Pharmacol Exp Ther (2001) 0.84
Psychotomimetic-induction of tissue plasminogen activator mRNA in corticostriatal neurons in rat brain. Eur J Neurosci (1998) 0.84
Increased sensitivity to cocaine, and over-responding during cocaine self-administration in tPA knockout mice. Brain Res (1999) 0.81
Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report. Drug Alcohol Depend (2001) 0.81
Drug dependence, synaptic plasticity, and tissue plasminogen activator. J Pharmacol Sci (2005) 0.80
Reinforcing effects of morphine are reduced in tissue plasminogen activator-knockout mice. Neuroscience (2007) 0.78
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet (2003) 4.41
Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry (2007) 4.37
Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) (2002) 3.74
Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry (2006) 3.55
Peripheral regeneration. Annu Rev Neurosci (2007) 2.94
Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron (2010) 2.37
Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A (2008) 2.27
Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology (Berl) (2003) 2.27
Effects of extended access to high versus low cocaine doses on self-administration, cocaine-induced reinstatement and brain mRNA levels in rats. Psychopharmacology (Berl) (2004) 2.02
Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry (2011) 2.01
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med (2007) 1.91
Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective. Drug Alcohol Depend (2012) 1.88
Laminin gamma1 is critical for Schwann cell differentiation, axon myelination, and regeneration in the peripheral nerve. J Cell Biol (2003) 1.78
The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem (2007) 1.78
Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci (2003) 1.72
The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci (2003) 1.71
Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology (2005) 1.66
Frequency of recent cocaine and alcohol use affects drug craving and associated responses to stress and drug-related cues. Psychoneuroendocrinology (2005) 1.66
Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood (2012) 1.65
Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci U S A (2005) 1.59
Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem (2004) 1.58
Schwann cell-specific ablation of laminin gamma1 causes apoptosis and prevents proliferation. J Neurosci (2005) 1.58
Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci U S A (2004) 1.54
Something of value: the introduction of contingency management interventions into the New York City Health and Hospital Addiction Treatment Service. J Subst Abuse Treat (2005) 1.52
Differential gene expression in the rat caudate putamen after "binge" cocaine administration: advantage of triplicate microarray analysis. Synapse (2003) 1.50
Carbon dioxide-induced anesthesia results in a rapid increase in plasma levels of vasopressin. Endocrinology (2009) 1.49
The Kreek-McHugh-Schluger-Kellogg scale: a new, rapid method for quantifying substance abuse and its possible applications. Drug Alcohol Depend (2003) 1.48
Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation. Neuron (2002) 1.48
Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A (2005) 1.45
Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) (2005) 1.43
Reactivity to laboratory stress provocation predicts relapse to cocaine. Drug Alcohol Depend (2009) 1.42
Transcriptional signatures of cellular plasticity in mice lacking the alpha1 subunit of GABAA receptors. J Neurosci (2006) 1.35
Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. J Endocrinol (2006) 1.34
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology (2005) 1.34
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet (2008) 1.33
Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci (2002) 1.31
Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci U S A (2008) 1.30
Both laminin and Schwann cell dystroglycan are necessary for proper clustering of sodium channels at nodes of Ranvier. J Neurosci (2005) 1.30
κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci (2012) 1.29
Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A (2010) 1.28
Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction (2007) 1.24
Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology (2008) 1.23
Effects of gender and cigarette smoking on reactivity to psychological and pharmacological stress provocation. Psychoneuroendocrinology (2008) 1.23
Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost (2005) 1.23
Microarray studies of psychostimulant-induced changes in gene expression. Addict Biol (2005) 1.22
Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin. Neuropsychopharmacology (2007) 1.21
Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) (2004) 1.21
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Gender differences in cardiovascular and corticoadrenal response to stress and drug cues in cocaine dependent individuals. Psychopharmacology (Berl) (2006) 1.19
Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. Arch Gen Psychiatry (2009) 1.17
The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) (2003) 1.17
Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci (2010) 1.16
Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry (2005) 1.16
Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics (2004) 1.16
Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc Natl Acad Sci U S A (2004) 1.15
Tissue plasminogen activator and NMDA receptor cleavage. Nat Med (2003) 1.14
Regulation of Schwann cell function by the extracellular matrix. Glia (2008) 1.14
Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse (2005) 1.13
Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am J Pathol (2006) 1.13
Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci (2010) 1.13
Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther (2008) 1.12
Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther (2006) 1.12
Cortical deficiency of laminin gamma1 impairs the AKT/GSK-3beta signaling pathway and leads to defects in neurite outgrowth and neuronal migration. Dev Biol (2008) 1.08
Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology (2002) 1.08
Conditioned place preference after single doses or "binge" cocaine in C57BL/6J and 129/J mice. Pharmacol Biochem Behav (2002) 1.07
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology (2008) 1.07
Increased AMPA GluR1 receptor subunit labeling on the plasma membrane of dendrites in the basolateral amygdala of rats self-administering morphine. Synapse (2005) 1.07
Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict Biol (2007) 1.06
Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis (2012) 1.06
Region-specific changes in the subcellular distribution of AMPA receptor GluR1 subunit in the rat ventral tegmental area after acute or chronic morphine administration. J Neurosci (2008) 1.05
Chronic immobilization stress alters aspects of emotionality and associative learning in the rat. Behav Neurosci (2008) 1.05
The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology (2006) 1.05
Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes. Pharmacogenet Genomics (2006) 1.05
Locomotion, stereotypy, and dopamine D1 receptors after chronic "binge" cocaine in C57BL/6J and 129/J mice. Pharmacol Biochem Behav (2003) 1.05
TPH2 and TPH1: association of variants and interactions with heroin addiction. Behav Genet (2008) 1.04
The genetics of the opioid system and specific drug addictions. Hum Genet (2012) 1.04
Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) (2004) 1.04
Former heroin addicts with or without a history of cocaine dependence are more impulsive than controls. Drug Alcohol Depend (2012) 1.02
Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates. J Pharmacol Exp Ther (2004) 1.02
Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet (2002) 1.02
Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice. Neuropsychopharmacology (2008) 1.02
Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. Brain Res (2009) 1.01
Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther (2003) 1.01
The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J Cereb Blood Flow Metab (2013) 1.01
Schwann cell myelination requires integration of laminin activities. J Cell Sci (2012) 1.00
Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene. Neuropsychopharmacology (2006) 1.00
Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment. J Addict Dis (2002) 1.00
Increased CRH mRNA levels in the rat amygdala during short-term withdrawal from chronic 'binge' cocaine. Brain Res Mol Brain Res (2003) 1.00
Ethnic diversity of DNA methylation in the OPRM1 promoter region in lymphocytes of heroin addicts. Hum Genet (2010) 1.00
High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. J Addict Dis (2006) 0.99
Genome-wide association study identifies genes that may contribute to risk for developing heroin addiction. Psychiatr Genet (2010) 0.99
Sex-specific dissociations in autonomic and HPA responses to stress and cues in alcohol-dependent patients with cocaine abuse. Alcohol Alcohol (2009) 0.99
Steady-dose and escalating-dose "binge" administration of cocaine alter expression of behavioral stereotypy and striatal preprodynorphin mRNA levels in rats. Brain Res Bull (2005) 0.98
Effects of high-dose methadone maintenance on cocaine place conditioning, cocaine self-administration, and mu-opioid receptor mRNA expression in the rat brain. Neuropsychopharmacology (2005) 0.97